v3.21.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Schedule of cash and cash equivalents
   June 30,
2021
   December  31,
2020
 
Cash and cash equivalents  $73,093,132   $41,905,469 

Restricted cash, short-term and long-term

   240,083    191,314 
Total cash, cash equivalents and restricted cash  $73,333,215   $42,096,783 

 

Schedule of marketable securities

 

June 30, 2021:

  Amortized
Cost
   Gross
Unrealized
Losses
   Gross
Unrealized
Gains
   Fair Value 
Money Market Funds included in Cash Equivalents  $17,478,369   $
-
   $
-
   $17,478,369 
Corporate Securities   3,561,926    (1,584)        3,560,342 
Commercial Paper   1,598,744    
-
    267    1,599,011 
Subtotal   5,160,670    (1,584)   267    5,159,353 
Total June 30, 2021  $22,639,039   $(1,584)  $267   $22,637,722 
December 31, 2020:                    
Money Market Funds included in Cash Equivalents  $3,182,762   $(81)  $8   $3,182,689 
Corporate Securities   3,565,501    (1,005)   3    3,564,499 
Commercial Paper   879,501    
-
    72    879,573 
Subtotal   4,445,002    (1,005)   75    4,444,072 
Total December 31, 2020  $7,627,764   $(1,086)  $83   $7,626,761 

 

Schedule of carrying and fair value of financial assets
June 30, 2021:  Carrying Value   Level 1   Level 2   Level 3 
Money Market Funds and Cash Equivalents  $17,478,369   $17,478,369   $
-
   $
       -
 
Corporate Securities   3,560,342    
-
    3,560,342    
-
 
Commercial Paper   1,599,011    
-
    1,599,011    
-
 
Subtotal   5,159,353    
-
    5,159,353   $
-
 
Total June 30, 2021  $22,637,722   $17,478,369   $5,159,353   $
-
 
December 31, 2020:                    
Money Market Funds and Cash Equivalents  $3,182,689   $3,182,689   $
-
   $
-
 
Corporate Securities   3,564,499    
-
    3,564,499    
-
 
Commercial Paper   879,573    
-
    879,573    
-
 
Subtotal   4,444,072    
-
    4,444,072    
-
 
Total December 31, 2020  $7,626,761   $3,182,689   $4,444,072   $
-
 

 

Schedule of inventories
   June 30,
2021
   December 31,
2020
 
Finished goods  $245,668   $317,733 
Inventory reserve   (172,941)   (174,169)
Total  $72,727   $143,564 

 

Schedule of accrued expenses
   June 30,
2021
   December 31,
2020
 
Professional and consulting fees  $234,041   $146,129 
Accrued payroll and payroll taxes   1,432,414    2,490,441 
Clinical trial related   1,000    2,187 
Manufacturing development related   278,305    143,780 
Other   118,609    141,814 
Total  $2,064,369   $2,924,351 

 

Schedule of anti-dilutive securities excluded from calculation of diluted net loss per share
   Six Months Ended
June 30,
 
   2021   2020 
   (Number of Shares of
Common Stock Issuable)
 
Series C non-voting preferred stock   4,000    104,000 
Series E non-voting preferred stock   391,953    391,953 
Series G non-voting preferred stock   5,004,069    5,560,137 
Restricted stock units   
-
    105 
Shares issuable for payment of deferred board compensation   48,909    40,556 
Shares underlying outstanding warrants   56,455    183,148 
Shares underlying outstanding stock options   3,765,746    2,300,937 
Total potentially dilutive shares   9,271,132    8,580,836